Rilatelpo peptide injection has a new indication in China and has been accepted for application.

On November 13th, the official website of the CDE showed that the new indication for the insulin pump injection of tirzepatide, a dual agonist of glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide, has been accepted for marketing application by Lilly. This is the third indication for this drug in China to be approved after another application.